Global Gastroparesis Drugs Market 2024-2028

The gastroparesis drugs market is forecasted to grow by USD 1,421.42 mn during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the gastroparesis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of diabetes, increasing prevalence of gastroparesis, and increasing awareness about gastroparesis.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	3.53%
CAGR	3.69%
Incremental Value	$1421.42mn

Technavio's gastroparesis drugs market is segmented as below:

By Drug Class

Prokinetic agents
Antiemetics
Botulinum toxin injection

By Disease Type

Idiopathic gastroparesis
Diabetic gastroparesis
Post-surgical gastroparesis

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increasing growth opportunities in emerging markets as one of the prime reasons driving the gastroparesis drugs market growth during the next few years. Also, increasing number of clinical research and rising funding in healthcare industry will lead to sizable demand in the market.

The report on the gastroparesis drugs market covers the following areas:

Gastroparesis drugs market sizing
Gastroparesis drugs market forecast
Gastroparesis drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastroparesis drugs market vendors that include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc.. Also, the gastroparesis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76697

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Disease Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global gastroparesis drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global gastroparesis drugs market 2018 - 2022 ($ million)
4.2 Drug Class Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.3 Disease Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Disease Type Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 Prokinetic agents - Market size and forecast 2023-2028
Exhibit 34: Chart on Prokinetic agents - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Prokinetic agents - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Prokinetic agents - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Prokinetic agents - Year-over-year growth 2023-2028 (%)
6.4 Antiemetics - Market size and forecast 2023-2028
Exhibit 38: Chart on Antiemetics - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Antiemetics - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Antiemetics - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Antiemetics - Year-over-year growth 2023-2028 (%)
6.5 Botulinum toxin injection - Market size and forecast 2023-2028
Exhibit 42: Chart on Botulinum toxin injection - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Botulinum toxin injection - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Botulinum toxin injection - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Botulinum toxin injection - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Drug Class
Exhibit 46: Market opportunity by Drug Class ($ million)
Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Disease Type

7.1 Market segments
Exhibit 48: Chart on Disease Type - Market share 2023-2028 (%)
Exhibit 49: Data Table on Disease Type - Market share 2023-2028 (%)
7.2 Comparison by Disease Type
Exhibit 50: Chart on Comparison by Disease Type
Exhibit 51: Data Table on Comparison by Disease Type
7.3 Idiopathic gastroparesis - Market size and forecast 2023-2028
Exhibit 52: Chart on Idiopathic gastroparesis - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Idiopathic gastroparesis - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Idiopathic gastroparesis - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Idiopathic gastroparesis - Year-over-year growth 2023-2028 (%)
7.4 Diabetic gastroparesis - Market size and forecast 2023-2028
Exhibit 56: Chart on Diabetic gastroparesis - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Diabetic gastroparesis - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Diabetic gastroparesis - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Diabetic gastroparesis - Year-over-year growth 2023-2028 (%)
7.5 Post-surgical gastroparesis - Market size and forecast 2023-2028
Exhibit 60: Chart on Post-surgical gastroparesis - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Post-surgical gastroparesis - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Post-surgical gastroparesis - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Post-surgical gastroparesis - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Disease Type
Exhibit 64: Market opportunity by Disease Type ($ million)
Exhibit 65: Data Table on Market opportunity by Disease Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2023-2028 (%)
Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ million)
Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 115: Abbott Laboratories - Overview
Exhibit 116: Abbott Laboratories - Business segments
Exhibit 117: Abbott Laboratories - Key news
Exhibit 118: Abbott Laboratories - Key offerings
Exhibit 119: Abbott Laboratories - Segment focus
12.4 AbbVie Inc.
Exhibit 120: AbbVie Inc. - Overview
Exhibit 121: AbbVie Inc. - Product / Service
Exhibit 122: AbbVie Inc. - Key news
Exhibit 123: AbbVie Inc. - Key offerings
12.5 ANI Pharmaceuticals Inc.
Exhibit 124: ANI Pharmaceuticals Inc. - Overview
Exhibit 125: ANI Pharmaceuticals Inc. - Product / Service
Exhibit 126: ANI Pharmaceuticals Inc. - Key offerings
12.6 Bausch Health Companies Inc.
Exhibit 127: Bausch Health Companies Inc. - Overview
Exhibit 128: Bausch Health Companies Inc. - Business segments
Exhibit 129: Bausch Health Companies Inc. - Key news
Exhibit 130: Bausch Health Companies Inc. - Key offerings
Exhibit 131: Bausch Health Companies Inc. - Segment focus
12.7 Cadila Pharmaceuticals Ltd.
Exhibit 132: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 133: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 134: Cadila Pharmaceuticals Ltd. - Key offerings
12.8 Eisai Co. Ltd.
Exhibit 135: Eisai Co. Ltd. - Overview
Exhibit 136: Eisai Co. Ltd. - Business segments
Exhibit 137: Eisai Co. Ltd. - Key offerings
Exhibit 138: Eisai Co. Ltd. - Segment focus
12.9 Evoke Pharma Inc.
Exhibit 139: Evoke Pharma Inc. - Overview
Exhibit 140: Evoke Pharma Inc. - Product / Service
Exhibit 141: Evoke Pharma Inc. - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 142: GlaxoSmithKline Plc - Overview
Exhibit 143: GlaxoSmithKline Plc - Business segments
Exhibit 144: GlaxoSmithKline Plc - Key news
Exhibit 145: GlaxoSmithKline Plc - Key offerings
Exhibit 146: GlaxoSmithKline Plc - Segment focus
12.11 Ipca Laboratories Ltd.
Exhibit 147: Ipca Laboratories Ltd. - Overview
Exhibit 148: Ipca Laboratories Ltd. - Product / Service
Exhibit 149: Ipca Laboratories Ltd. - Key offerings
12.12 Medtronic Plc
Exhibit 150: Medtronic Plc - Overview
Exhibit 151: Medtronic Plc - Business segments
Exhibit 152: Medtronic Plc - Key news
Exhibit 153: Medtronic Plc - Key offerings
Exhibit 154: Medtronic Plc - Segment focus
12.13 Otsuka Pharmaceutical Co. Ltd.
Exhibit 155: Otsuka Pharmaceutical Co. Ltd. - Overview
Exhibit 156: Otsuka Pharmaceutical Co. Ltd. - Product / Service
Exhibit 157: Otsuka Pharmaceutical Co. Ltd. - Key offerings
12.14 Pfizer Inc.
Exhibit 158: Pfizer Inc. - Overview
Exhibit 159: Pfizer Inc. - Product / Service
Exhibit 160: Pfizer Inc. - Key news
Exhibit 161: Pfizer Inc. - Key offerings
12.15 Processa Pharmaceuticals Inc.
Exhibit 162: Processa Pharmaceuticals Inc. - Overview
Exhibit 163: Processa Pharmaceuticals Inc. - Product / Service
Exhibit 164: Processa Pharmaceuticals Inc. - Key offerings
12.16 Takeda Pharmaceutical Co. Ltd.
Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings
12.17 Vanda Pharmaceuticals Inc.
Exhibit 169: Vanda Pharmaceuticals Inc. - Overview
Exhibit 170: Vanda Pharmaceuticals Inc. - Product / Service
Exhibit 171: Vanda Pharmaceuticals Inc. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 172: Inclusions checklist
Exhibit 173: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 174: Currency conversion rates for US$
13.4 Research methodology
Exhibit 175: Research methodology
Exhibit 176: Validation techniques employed for market sizing
Exhibit 177: Information sources
13.5 List of abbreviations
Exhibit 178: List of abbreviations